Targeting HER2 in Nuclear Medicine for Imaging and Therapy
Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presently, there are 2 standard diagnostic techniques to assess HER2 status in biopsies: immunohistochemistry and fluorescence in situ hybridization. While these techniques have played an important role in...
Saved in:
Main Authors: | Adriana V. F. Massicano PhD, Bernadette V. Marquez-Nostra PhD, Suzanne E. Lapi PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-01-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.1177/1536012117745386 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combining Nuclear Medicine With
Other Modalities: Future Prospect for Multimodality Imaging
by: Stephen J. Archibald PhD, et al.
Published: (2024-01-01) -
Detecting Demyelination by PET: The Lesion as Imaging Target
by: Pedro Brugarolas PhD, et al.
Published: (2018-07-01) -
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
by: Vidya Narayanaswami PhD, et al.
Published: (2018-09-01) -
Swelling of the Right Arm During a Nuclear Medicine Therapy for Metastatic Pheochromocytoma
by: Run Yu, MD, PhD, et al.
Published: (2025-01-01) -
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
by: Song Dong, PhD, et al.
Published: (2025-01-01)